Skip to main content

Table 1 Human cases analyzed in this study.

From: A Modification-Specific Peptide-Based immunization Approach Using CRM197 Carrier Protein: Development of a Selective Vaccine Against Pyroglutamate Aβ Peptides

Case #

Clinical Dx

Braak

Age

Sex

Region

3665

Normal

0

85

Female

Mid-temporal cortex

4323

Normal

0

93

Female

Mid-temporal cortex

4359

Normal

0

92

Male

Mid-temporal cortex

4428

Normal

0

84

Female

Mid-temporal cortex

4860

Normal

0

92

Female

Mid-temporal cortex

4870

Normal

0

99

Female

Mid-temporal cortex

3410

AD

V-VI

81

Male

Mid-temporal cortex

4073

AD

V-VI

78

Female

Mid-temporal cortex

4137

AD

V-VI

88

Male

Mid-temporal cortex

5175

AD

V-VI

56

Female

Mid-temporal cortex

5288

AD

V-VI

81

Male

Mid-temporal cortex

5340

AD

V-VI

54

Male

Mid-temporal cortex

  1. AD, Alzheimer’s disease. Cases were obtained from the Albert Einstein College of Medicine human brain bank, Bronx, NY.